Cannabinoid receptors: A brief history and "what's hot"

Frontiers in Bioscience

Volumn 14, Issue 3, 2009, Pages 944-957

  Graham, Euan Scott ^a   Ashton, John Clive ^b   Glass, Michelle ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anandamide; Arthritis; Cannabinoid; Endocannabinoid; Immune cell; Ischemia; Multiple sclerosis; Oligimerisation; Pain; Receptor signalling; Review

Indexed keywords

CANNABINOID RECEPTOR; LIGAND;

CHEMISTRY; DRUG EFFECT; HUMAN; INFLAMMATION; METABOLISM; MULTIPLE SCLEROSIS; OBESITY; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD;

HUMANS; INFLAMMATION; LIGANDS; MULTIPLE SCLEROSIS; OBESITY; PAIN; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 63849237026     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3288     Document Type: Article

References (142)

1. J Ashton, M Glass. The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Current Neuropharmacology 5, 73-80. (2007). (Pubitemid 47019422)
2. D Cota. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23, 507-17. (2007). (Pubitemid 350018024)
3. C Benito, RM Tolon, MR Pazos, E Nunez, AI Castillo, J Romero. Cannabinoid CB (2) receptors in human brain inflammation. Br J Pharmacol 153, 277-85. (2008).
4. Y Gaoni, R Mechoulam. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86, 1646-1647. (1964).
5. R Mechoulam, Y Gaoni. The absolute configuration of delta-1- tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12, 1109-11. (1967).
6. SH Roth. Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 56, 968-75. (1978). (Pubitemid 9133774)
7. WL Dewey. Cannabinoid pharmacology. Pharmacol Rev 38, 151-78. (1986). (Pubitemid 16001329)
8. WA Devane, FA Dysarz, 3rd, MR Johnson, LS Melvin, AC Howlett. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34, 605-13. (1988). (Pubitemid 19007296)
9. AC Howlett. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35, 1803-10. (1984). (Pubitemid 14033077)
10. AC Howlett. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27, 429-36. (1985). (Pubitemid 15088930)
11. AC Howlett, JM Qualy, LL Khachatrian. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29, 307-13. (1986). (Pubitemid 16137598)
12. LS Melvin, MR Johnson. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res Monogr 79, 31-47. (1987).
13. M Herkenham, AB Lynn, MD Little, MR Johnson, LS Melvin, BR de Costa, KC Rice. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87, 1932-6. (1990).
14. LA Matsuda, SJ Lolait, MJ Brownstein, AC Young, TI Bonner. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-4. (1990).
15. SH Snyder. Pharmacology: planning for serendipity. Nature 346, 508. (1990).
16. M Herkenham, AB Lynn, BR de Costa, EK Richfield. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547, 267-74. (1991).
17. M Glass, M Dragunow, RL Faull. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318. (1997). (Pubitemid 27079604)
18. G Nyiri, C Cserep, E Szabadits, K Mackie, TF Freund. CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136, 811-22. (2005). (Pubitemid 41774726)
19. G Nyiri, E Szabadits, C Cserep, K Mackie, R Shigemoto, TF Freund. GABAB and CB1 cannabinoid receptor expression identifies two types of septal cholinergic neurons. Eur J Neurosci 21, 3034-42. (2005). (Pubitemid 40917067)
20. CS Breivogel, LJ Sim, SR Childers. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282, 1632-42. (1997). (Pubitemid 27408350)
21. S Munro, KL Thomas, M Abu-Shaar. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-5. (1993). (Pubitemid 23305569)
22. MD Van Sickle, M Duncan, PJ Kingsley, A Mouihate, P Urbani, K Mackie, N Stella, A Makriyannis, D Piomelli, JS Davison, LJ Marnett, V Di Marzo, QJ Pittman, KD Patel, KA Sharkey. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-32. (2005). (Pubitemid 41457202)
23. O Ofek, M Karsak, N Leclerc, M Fogel, B Frenkel, K Wright, J Tam, M Attar-Namdar, V Kram, E Shohami, R Mechoulam, A Zimmer, I Bab. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 103, 696-701. (2006). (Pubitemid 43153088)
24. X Xu, Y Liu, S Huang, G Liu, C Xie, J Zhou, W Fan, Q Li, Q Wang, D Zhong, X Miao. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171, 31-8. (2006). (Pubitemid 44635750)
25. CS Breivogel, G Griffin, V Di Marzo, BR Martin. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60, 155-63. (2001). (Pubitemid 32595243)
26. D Baker, G Pryce, WL Davies, CR Hiley. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27, 1-4. (2006). (Pubitemid 43063115)
27. M Sawzdargo, T Nguyen, DK Lee, KR Lynch, R Cheng, HHQ Heng, SR George, BF O'Dowd. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, (Psi)GPR53 and GPR55: GPR55 is extensively expressed in human brain. Molecular Brain Research 64, 193-198. (1999). (Pubitemid 29052470)
28. E Ryberg, N Larsson, S Sjogren, S Hjorth, NO Hermansson, J Leonova, T Elebring, K Nilsson, T Drmota, PJ Greasley. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152, 1092-101. (2007). (Pubitemid 350166046)
29. S Oka, K Nakajima, A Yamashita, S Kishimoto, T Sugiura. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362, 928-34. (2007). (Pubitemid 47390663)
30. WA Devane, L Hanus, A Breuer, RG Pertwee, LA Stevenson, G Griffin, D Gibson, A Mandelbaum, A Etinger, R Mechoulam. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-9. (1992). (Pubitemid 23026736)
31. T Sugiura, S Kondo, A Sukagawa, S Nakane, A Shinoda, K Itoh, A Yamashita, K Waku. 2- Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215, 89-97. (1995).
32. R Mechoulam, S Ben-Shabat, L Hanus, M Ligumsky, NE Kaminski, AR Schatz, A Gopher, S Almog, BR Martin, DR Compton, et al.. Identification of an endogenous 2- monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90. (1995).
33. L Hanus, S Abu-Lafi, E Fride, A Breuer, Z Vogel, DE Shalev, I Kustanovich, R Mechoulam. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98, 3662-5. (2001). (Pubitemid 32249827)
34. AC Porter, JM Sauer, MD Knierman, GW Becker, MJ Berna, J Bao, GG Nomikos, P Carter, FP Bymaster, AB Leese, CC Felder. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301, 1020-4. (2002). (Pubitemid 34595094)
35. Y Okamoto, J Morishita, K Tsuboi, T Tonai, N Ueda. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279, 5298-305. (2004). (Pubitemid 38220550)
36. V Di Marzo, A Fontana, H Cadas, S Schinelli, G Cimino, JC Schwartz, D Piomelli. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-91. (1994).
37. H Cadas, E di Tomaso, D Piomelli. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 17, 1226-42. (1997). (Pubitemid 27073726)
38. H Cadas, S Gaillet, M Beltramo, L Venance, D Piomelli. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 16, 3934-42. (1996). (Pubitemid 26176057)
39. BF Cravatt, DK Giang, SP Mayfield, DL Boger, RA Lerner, NB Gilula. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-7. (1996). (Pubitemid 26374593)
40. MK McKinney, BF Cravatt. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74, 411-32. (2005). (Pubitemid 40995513)
41. V Di Marzo, L De Petrocellis, T Bisogno. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol, 147-85. (2005).
42. T Bisogno, F Howell, G Williams, A Minassi, MG Cascio, A Ligresti, I Matias, A Schiano-Moriello, P Paul, EJ Williams, U Gangadharan, C Hobbs, V Di Marzo, P Doherty. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163, 463-8. (2003). (Pubitemid 37429860)
43. T Yoshida, M Fukaya, M Uchigashima, E Miura, H Kamiya, M Kano, M Watanabe. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26, 4740-51. (2006). (Pubitemid 44315313)
44. T Ohno-Shosaku, T Maejima, M Kano. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-38. (2001). (Pubitemid 32323945)
45. V Di Marzo, T Bisogno, T Sugiura, D Melck, L De Petrocellis. The novel endogenous cannabinoid 2- arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331 ( Pt 1), 15-9. (1998). (Pubitemid 28163951)
46. SK Goparaju, N Ueda, H Yamaguchi, S Yamamoto. Anandamide amidohydrolase reacting with 2- arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422, 69-73. (1998). (Pubitemid 28052868)
47. SK Goparaju, N Ueda, K Taniguchi, S Yamamoto. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57, 417-23. (1999). (Pubitemid 29065290)
48. TP Dinh, D Carpenter, FM Leslie, TF Freund, I Katona, SL Sensi, S Kathuria, D Piomelli. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99, 10819-24. (2002).
49. JL Blankman, GM Simon, BF Cravatt. A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol. Chem Biol 14, 1347-56. (2007). (Pubitemid 350257008)
50. M Glass, CC Felder. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17, 5327-33. (1997).
51. CS Kearn, K Blake-Palmer, E Daniel, K Mackie, M Glass. Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk? Mol Pharmacol 67, 1697-704. (2005). (Pubitemid 40594170)
52. JE Lauckner, B Hille, K Mackie. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 102, 19144-9. (2005). (Pubitemid 43049580)
53. K Mackie, B Hille. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89, 3825-9. (1992).
54. D Gebremedhin, AR Lange, WB Campbell, CJ Hillard, DR Harder. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 276, H2085-93. (1999). (Pubitemid 29323495)
55. K Mackie, Y Lai, R Westenbroek, R Mitchell. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15, 6552-61. (1995).
56. M Wartmann, D Campbell, A Subramanian, SH Burstein, RJ Davis. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 359, 133-6. (1995).
57. ES Graham, N Ball, EL Scotter, P Narayan, M Dragunow, M Glass. Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. J Biol Chem 281, 29085-95. (2006). (Pubitemid 44507052)
58. J Liu, B Gao, F Mirshahi, AJ Sanyal, AD Khanolkar, A Makriyannis, G Kunos. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 Pt 3, 835-40. (2000). (Pubitemid 30171048)
59. P Derkinderen, C Ledent, M Parmentier, JA Girault. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem 77, 957-60. (2001). (Pubitemid 32466793)
60. D Rueda, I Galve-Roperh, A Haro, M Guzman. The CB (1) cannabinoid receptor is coupled to the activation of c- Jun N-terminal kinase. Mol Pharmacol 58, 814-20. (2000).
61. I Galve-Roperh, D Rueda, T Gomez del Pulgar, G Velasco, M Guzman. Mechanism of extracellular signal-regulated kinase activation by the CB (1) cannabinoid receptor. Mol Pharmacol 62, 1385-92. (2002). (Pubitemid 35403833)
62. C Sanchez, D Rueda, B Segui, I Galve-Roperh, T Levade, M Guzman. The CB (1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol Pharmacol 59, 955-9. (2001). (Pubitemid 32381572)
63. CC Felder, KE Joyce, EM Briley, J Mansouri, K Mackie, O Blond, Y Lai, AL Ma, RL Mitchell. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48, 443-50. (1995).
64. Y Kobayashi, S Arai, K Waku, T Sugiura. Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. J Biochem 129, 665-9. (2001). (Pubitemid 32499776)
65. SD McAllister, G Griffin, LS Satin, ME Abood. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291, 618-26. (1999). (Pubitemid 29503533)
66. B Calandra, M Portier, A Kerneis, M Delpech, C Carillon, G Le Fur, P Ferrara, D Shire. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol 374, 445-55. (1999). (Pubitemid 29313457)
67. MG Sanchez, L Ruiz-Llorente, AM Sanchez, I Diaz- Laviada. Activation of phosphoinositide 3-kinase/PKB pathway by CB (1) and CB (2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15, 851-9. (2003). (Pubitemid 36776659)
68. C Zoratti, D Kipmen-Korgun, K Osibow, R Malli, WF Graier. Anandamide initiates Ca (2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol 140, 1351-62. (2003). (Pubitemid 38067842)
69. M Rajesh, P Mukhopadhyay, S Batkai, G Hasko, L Liaudet, JW Huffman, A Csiszar, Z Ungvari, K Mackie, S Chatterjee, P Pacher. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293, H2210-8. (2007). (Pubitemid 47605864)
70. CM Williams, TC Kirkham. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143, 315-7. (1999). (Pubitemid 29204987)
71. DB Vaupel, EC Morton. Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacol Biochem Behav 17, 539-45. (1982). (Pubitemid 12037670)
72. CM Williams, PJ Rogers, TC Kirkham. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 65, 343-6. (1998). (Pubitemid 28548657)
73. CM Williams, TC Kirkham. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71, 333-40. (2002).
74. G Colombo, R Agabio, G Diaz, C Lobina, R Reali, GL Gessa. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63, PL113-7. (1998).
75. V Di Marzo, SK Goparaju, L Wang, J Liu, S Batkai, Z Jarai, F Fezza, GI Miura, RD Palmiter, T Sugiura, G Kunos. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-5. (2001). (Pubitemid 32303781)
76. JP Despres. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol 6, 46-50. (2007).
77. L Bellocchio, G Mancini, V Vicennati, R Pasquali, U Pagotto. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol 6, 586-91. (2006). (Pubitemid 44660950)
78. A Castane, F Berrendero, R Maldonado. The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 81, 381-6. (2005). (Pubitemid 40807135)
79. C Filozof, MC Fernandez Pinilla, A Fernandez-Cruz. Smoking cessation and weight gain. Obes Rev 5, 95-103. (2004). (Pubitemid 38623163)
80. K Cahill, M Ussher. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev, CD005353. (2007).
81. JJ Rodriguez, K Mackie, VM Pickel. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21, 823-33. (2001). (Pubitemid 32163123)
82. VM Pickel, J Chan, TL Kash, JJ Rodriguez, K MacKie. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127, 101-12. (2004). (Pubitemid 38829156)
83. M Herkenham, AB Lynn, MR Johnson, LS Melvin, BR de Costa, KC Rice. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11, 563-83. (1991).
84. AF Hoffman, CR Lupica. Mechanisms of cannabinoid inhibition of GABA (A) synaptic transmission in the hippocampus. J Neurosci 20, 2470-9. (2000). (Pubitemid 30220334)
85. I Katona, EA Rancz, L Acsady, C Ledent, K Mackie, N Hajos, TF Freund. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21, 9506-18. (2001). (Pubitemid 33096895)
86. M Glass, M Dragunow, RL Faull. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA (A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-19. (2000). (Pubitemid 30320757)
87. D Baker, SJ Jackson, G Pryce. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 152, 649-54. (2007). (Pubitemid 350034985)
88. JC Ashton, RM Rahman, SM Nair, BA Sutherland, M Glass, I Appleton. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412, 114-7. (2007). (Pubitemid 46074356)
89. I Lastres-Becker, F Molina-Holgado, JA Ramos, R Mechoulam, J Fernandez-Ruiz. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19, 96-107. (2005). (Pubitemid 40544727)
90. BG Ramirez, C Blazquez, T Gomez del Pulgar, M Guzman, ML de Ceballos. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-13. (2005). (Pubitemid 40289395)
91. G Pryce, Z Ahmed, DJ Hankey, SJ Jackson, JL Croxford, JM Pocock, C Ledent, A Petzold, AJ Thompson, G Giovannoni, ML Cuzner, D Baker. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-202. (2003). (Pubitemid 37432364)
92. J Ellis, JD Pediani, M Canals, S Milasta, G Milligan. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and - independent coordinated alterations of receptor localization and function. J Biol Chem 281, 38812-24. (2006). (Pubitemid 46042008)
93. Z Xie, RG Bhushan, DJ Daniels, PS Portoghese. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68, 1079-86. (2005). (Pubitemid 41345799)
94. A Tappe-Theodor, N Agarwal, I Katona, T Rubino, L Martini, J Swiercz, K Mackie, H Monyer, D Parolaro, J Whistler, T Kuner, R Kuner. A molecular basis of analgesic tolerance to cannabinoids. J Neurosci 27, 4165-77. (2007). (Pubitemid 46597151)
95. JL Niehaus, Y Liu, KT Wallis, M Egertova, SG Bhartur, S Mukhopadhyay, S Shi, H He, DE Selley, AC Howlett, MR Elphick, DL Lewis. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol Pharmacol 72, 1557-66. (2007). (Pubitemid 350146092)
96. L Martini, M Waldhoer, M Pusch, V Kharazia, J Fong, JH Lee, C Freissmuth, JL Whistler. Ligand-induced down regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. Faseb J 21, 802-11. (2007). (Pubitemid 46348255)
97. A Arevalo-Martin, D Garcia-Ovejero, O Gomez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina- Holgado, F Molina-Holgado. CB (2) cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153, 216-25. (2008).
98. J Zhang, C Hoffert, HK Vu, T Groblewski, S Ahmad, D O'Donnell. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17, 2750-4. (2003). (Pubitemid 36819300)
99. A Arevalo-Martin, JM Vela, E Molina-Holgado, J Borrell, C Guaza. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23, 2511-6. (2003). (Pubitemid 36418583)
100. K Maresz, EJ Carrier, ED Ponomarev, CJ Hillard, BN Dittel. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95, 437-45. (2005). (Pubitemid 41457512)
101. M Beltramo, N Bernardini, R Bertorelli, M Campanella, E Nicolussi, S Fredduzzi, A Reggiani. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23, 1530-8. (2006).
102. S Mukhopadhyay, S Das, EA Williams, D Moore, JD Jones, DS Zahm, MM Ndengele, AJ Lechner, AC Howlett. Lipopolysaccharide and cyclic AMP regulation of CB (2) cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. J Neuroimmunol 181, 82-92. (2006). (Pubitemid 44827292)
103. L Walter, A Franklin, A Witting, C Wade, Y Xie, G Kunos, K Mackie, N Stella. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23, 1398-405. (2003). (Pubitemid 36258918)
104. EJ Carrier, CS Kearn, AJ Barkmeier, NM Breese, W Yang, K Nithipatikom, SL Pfister, WB Campbell, CJ Hillard. Cultured rat microglial cells synthesize the endocannabinoid 2- arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65, 999-1007. (2004). (Pubitemid 38420506)
105. J Ehrhart, D Obregon, T Mori, H Hou, N Sun, Y Bai, T Klein, F Fernandez, J Tan, RD Shytle. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2, 29. (2005).
106. A Klegeris, CJ Bissonnette, PL McGeer. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139, 775-86. (2003). (Pubitemid 36819605)
107. S Kreutz, M Koch, C Ghadban, HW Korf, F Dehghani. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol 203, 246- 57. (2007). (Pubitemid 44821182)
108. M Zhang, BR Martin, MW Adler, RK Razdan, JI Jallo, RF Tuma. Cannabinoid CB (2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27, 1387-96. (2007). (Pubitemid 46985356)
109. J Palazuelos, T Aguado, A Egia, R Mechoulam, M Guzman, I Galve-Roperh. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. Faseb J 20, 2405-7. (2006).
110. C Benito, JP Romero, RM Tolon, D Clemente, F Docagne, CJ Hillard, C Guaza, J Romero. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27, 2396-402. (2007). (Pubitemid 46340977)
111. J Held-Feindt, L Dorner, G Sahan, HM Mehdorn, R Mentlein. Cannabinoid receptors in human astroglial tumors. Journal of Neurochemistry 98, 886-893. (2006). (Pubitemid 44051288)
112. E Eljaschewitsch, A Witting, C Mawrin, T Lee, PM Schmidt, S Wolf, H Hoertnagl, CS Raine, R Schneider-Stock, R Nitsch, O Ullrich. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67-79. (2006). (Pubitemid 43017186)
113. KB Svendsen, TS Jensen, FW Bach. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bmj 329, 253. (2004).
114. J Wissel, T Haydn, J Muller, C Brenneis, T Berger, W Poewe, LD Schelosky. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 253, 1337-41. (2006). (Pubitemid 44691559)
115. DJ Rog, TJ Nurmikko, CA Young. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29, 2068-79. (2007). (Pubitemid 350218115)
116. DT Wade, PM Makela, H House, C Bateman, P Robson. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12, 639-45. (2006). (Pubitemid 46940638)
117. J Zajicek, P Fox, H Sanders, D Wright, J Vickery, A Nunn, A Thompson. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362, 1517-26. (2003). (Pubitemid 37410189)
118. JP Zajicek, HP Sanders, DE Wright, PJ Vickery, WM Ingram, SM Reilly, AJ Nunn, LJ Teare, PJ Fox, AJ Thompson. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76, 1664-1669. (2005). (Pubitemid 41697631)
119. K Maresz, G Pryce, ED Ponomarev, G Marsicano, JL Croxford, LP Shriver, C Ledent, X Cheng, EJ Carrier, MK Mann, G Giovannoni, RG Pertwee, T Yamamura, NE Buckley, CJ Hillard, B Lutz, D Baker, BN Dittel. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13, 492-7. (2007). (Pubitemid 46559830)
120. J Martinez-Orgado, B Fernandez-Frutos, R Gonzalez, E Romero, L Uriguen, J Romero, MP Viveros. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Brain Res Mol Brain Res 114, 132-9. (2003). (Pubitemid 36773554)
121. M Zhang, BR Martin, RK Razdan, MW Adler, D Ganea, RF Tuma. Modulating the balance between CB1 and CB2 receptor activation can protect the brain from ischemic damage. in 17th Annual Symposium on the Cannabinoids. 2007. Burlington, Vermont: International Cannabinoid Research Society.
122. FA Campbell, MR Tramer, D Carroll, DJ Reynolds, RA Moore, HJ McQuay. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Bmj 323, 13-6. (2001). (Pubitemid 32681998)
123. M Iskedjian, B Bereza, A Gordon, C Piwko, TR Einarson. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23, 17-24. (2007). (Pubitemid 46191666)
124. A Romero-Sandoval, JC Eisenach. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106, 787-94. (2007). (Pubitemid 46555623)
125. KJ Valenzano, L Tafesse, G Lee, JE Harrison, JM Boulet, SL Gottshall, L Mark, MS Pearson, W Miller, S Shan, L Rabadi, Y Rotshteyn, SM Chaffer, PI Turchin, DA Elsemore, M Toth, L Koetzner, GT Whiteside. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48, 658-72. (2005). (Pubitemid 40462406)
126. ED Milligan, C Twining, M Chacur, J Biedenkapp, K O'Connor, S Poole, K Tracey, D Martin, SF Maier, LR Watkins. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 23, 1026-40. (2003). (Pubitemid 36206195)
127. AG Nackley, RL Suplita, 2nd, AG Hohmann. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117, 659-70. (2003). (Pubitemid 36263159)
128. AG Nackley, AM Zvonok, A Makriyannis, AG Hohmann. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92, 3562-74. (2004). (Pubitemid 39506332)
129. PF Sumariwalla, R Gallily, S Tchilibon, E Fride, R Mechoulam, M Feldmann. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50, 985-98. (2004). (Pubitemid 38326200)
130. EC Mbvundula, RA Bunning, KD Rainsford. Arthritis and cannabinoids: HU-210 and Win-55, 212-2 prevent IL- 1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol 58, 351-8. (2006). (Pubitemid 43344578)
131. EC Mbvundula, RA Bunning, KD Rainsford. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem Pharmacol 69, 635-40. (2005).
132. RB Zurier, RG Rossetti, JH Lane, JM Goldberg, SA Hunter, SH Burstein. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41, 163- 70. (1998). (Pubitemid 28041935)
133. RB Zurier, RG Rossetti, SH Burstein, B Bidinger. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65, 649-55. (2003). (Pubitemid 36144252)
134. B Bidinger, R Torres, RG Rossetti, L Brown, R Beltre, S Burstein, JB Lian, GS Stein, RB Zurier. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108, 95-102. (2003). (Pubitemid 36960071)
135. DR Blake, P Robson, M Ho, RW Jubb, CS McCabe. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50-52. (2006). (Pubitemid 43033874)
136. I Bab, A Zimmer. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153, 182-8. (2008).
137. AI Idris, RJ van 't Hof, IR Greig, SA Ridge, D Baker, RA Ross, SH Ralston. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11, 774-9. (2005). (Pubitemid 41021210)
138. M Karsak, M Cohen-Solal, J Freudenberg, A Ostertag, C Morieux, U Kornak, J Essig, E Erxlebe, I Bab, C Kubisch, MC de Vernejoul, A Zimmer. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14, 3389-96. (2005). (Pubitemid 41672123)
139. J Tam, O Ofek, E Fride, C Ledent, Y Gabet, R Muller, A Zimmer, K Mackie, R Mechoulam, E Shohami, I Bab. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70, 786-92. (2006). (Pubitemid 44268435)
140. JM McPartland, RW Norris, CW Kilpatrick. Coevolution between cannabinoid receptors and endocannabinoid ligands. Gene 397, 126-35. (2007). (Pubitemid 46977139)
141. G Griffin, Q Tao, ME Abood. Cloning and pharmacological characterization of the rat CB (2) cannabinoid receptor. J Pharmacol Exp Ther 292, 886-94. (2000). (Pubitemid 30136579)
142. S Mukherjee, M Adams, K Whiteaker, A Daza, K Kage, S Cassar, M Meyer, BB Yao. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505, 1-9. (2004). (Pubitemid 39535670)